Section Arrow
BLTE.NASDAQ
- Belite Bio
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 171.93
0 (0.00%)
Bid
171.33
Ask
172.04
High 171.93 
Low 171.93 
Volume 203 
Regular Hours (Closed)
Last
 171.93
-1.25 (-0.72%)
Day High 
176.44 
Prev. Close
173.18 
1-M High
183.67 
Volume 
115.95K 
Bid
171.33
Ask
172.04
Day Low
171.045 
Open
172 
1-M Low
146.61 
Market Cap 
6.92B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 169.25 
20-SMA 162.64 
50-SMA 171.97 
52-W High 200 
52-W Low 53.595 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.31/0.08
Enterprise Value
6.92B
Balance Sheet
Book Value Per Share
19.28
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.18 -0.1 -4.39%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8501 -0.0599 -6.58%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.91 -0.04 -2.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includesa small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.